Skip to main content
Top
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression

Authors: Dirk Rades, Antonio J. Conde-Moreno, Jon Cacicedo, Theo Veninga, Barbara Segedin, Karmen Stanic, Steven E. Schild

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

Local progression-free survival (LPFS = stable or improved motor function/resolution of paraplegia during RT without in-field recurrence following RT) is important when treating metastatic spinal cord compression (MSCC). An instrument to estimate LPFS was created to identify patients appropriately treated with short-course RT instead of longer-course RT plus/minus decompressive surgery.

Methods

In 686 patients treated with 20 Gy in 5 fractions alone, ten characteristics were retrospectively analyzed for LPFS including age, interval between tumor diagnosis and RT of MSCC, visceral metastases, other bone metastases, primary tumor type, gender, time developing motor deficits, pre-RT gait function, number of vertebrae affected by MSCC, and performance score. Characteristics significantly (p < 0.05) associated with LPFS on multivariate analyses were incorporated in the scoring system. Six-month LPFS rates for significant characteristics were divided by 10, and corresponding points were added.

Results

On multivariate analyses, visceral metastases (p < 0.001), tumor type (p = 0.009), time developing motor deficits (p < 0.001) and performance score (p = 0.009) were associated with LPFS and used for the scoring system. Scores for patients ranged between 24 and 35 points. Three groups were designed: 24–28 (A), 29–31 (B) and 32–35 (C) points. Six-month LPFS rates were 46, 69 and 92%, 12-month LPFS rates 46, 63 and 83%. Median survival times were 2 months (61% died within 2 months), 4 months and ≥ 11 months (median not reached).

Conclusions

Most group A patients appeared sub-optimally treated with 20 Gy in 5 fractions. Patients with survival prognoses ≤2 months may be considered for best supportive care or single-fraction RT, those with prognoses ≥3 months for longer-course RT plus/minus upfront decompressive surgery. Many group B and most group C patients achieved long-time LPFS and appeared sufficiently treated with 20 Gy in 5 fractions. However, based on previous data, long-term survivors may benefit from longer-course RT.
Literature
3.
go back to reference Thirion P, O’Sullivan L, Clayton-Lea A, Small C, McArdle O, Kelly P, Parker I, O'Sullivan J, Hacking D, Collins C, Pomeroy M, Moriarty M. ICORG 05-03: prospective randomized non-inferiority phase 3 trial comparing two radiation schedules in malignant spinal cord compression not proceeding with surgical decompression. Int J Radiat Oncol Biol Phys. 2014;90(LBA2):1263–4.CrossRef Thirion P, O’Sullivan L, Clayton-Lea A, Small C, McArdle O, Kelly P, Parker I, O'Sullivan J, Hacking D, Collins C, Pomeroy M, Moriarty M. ICORG 05-03: prospective randomized non-inferiority phase 3 trial comparing two radiation schedules in malignant spinal cord compression not proceeding with surgical decompression. Int J Radiat Oncol Biol Phys. 2014;90(LBA2):1263–4.CrossRef
4.
go back to reference Hoskin P, Misra V, Hopkins K, Holt T, Brown G, Arnott S, Thomas SS, Reczko K, Beare S, Lopes A, Forsyth S. SCORAD III: randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). J Clin Oncol. 2017;35(suppl):abstr LBA10004.CrossRef Hoskin P, Misra V, Hopkins K, Holt T, Brown G, Arnott S, Thomas SS, Reczko K, Beare S, Lopes A, Forsyth S. SCORAD III: randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). J Clin Oncol. 2017;35(suppl):abstr LBA10004.CrossRef
7.
go back to reference Rades D, Šegedin B, Conde-Moreno AJ, Garcia R, Perpar A, Metz M, Badakhshi H, Schreiber A, Nitsche M, Hipp P, Schulze W, Adamietz IA, Norkus D, Rudat V, Cacicedo J, Schild SE. Radiotherapy with 4 Gy × 5 versus 3 Gy × 10 for metastatic epidural spinal cord compression: final results of the SCORE-2 trial (ARO 2009/01). J Clin Oncol. 2016;34:597–602. https://doi.org/10.1200/JCO.2015.64.0862.CrossRefPubMed Rades D, Šegedin B, Conde-Moreno AJ, Garcia R, Perpar A, Metz M, Badakhshi H, Schreiber A, Nitsche M, Hipp P, Schulze W, Adamietz IA, Norkus D, Rudat V, Cacicedo J, Schild SE. Radiotherapy with 4 Gy × 5 versus 3 Gy × 10 for metastatic epidural spinal cord compression: final results of the SCORE-2 trial (ARO 2009/01). J Clin Oncol. 2016;34:597–602. https://​doi.​org/​10.​1200/​JCO.​2015.​64.​0862.CrossRefPubMed
8.
go back to reference Rades D, Conde-Moreno AJ, Cacicedo J, Veninga T, Segedin B, Stanic K, Rudat V, Schild SE. 1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. Radiat Oncol. 2018;13:21.CrossRef Rades D, Conde-Moreno AJ, Cacicedo J, Veninga T, Segedin B, Stanic K, Rudat V, Schild SE. 1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. Radiat Oncol. 2018;13:21.CrossRef
9.
go back to reference Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabillic R, Karstens JH, Alberti W, Dunst J, Schild SE. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24:3388–93. https://doi.org/10.1200/JCO.2005.05.0542.CrossRefPubMed Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H, Bajrovic A, Hoskin PJ, Tribius S, Wildfang I, Rudat V, Engenhart-Cabillic R, Karstens JH, Alberti W, Dunst J, Schild SE. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol. 2006;24:3388–93. https://​doi.​org/​10.​1200/​JCO.​2005.​05.​0542.CrossRefPubMed
10.
go back to reference Tomita T, Galicich JH, Sundaresan N. Radiation therapy for spinal epidural metastases with complete block. Acta Radiol Oncol. 1983;22:135–43.CrossRef Tomita T, Galicich JH, Sundaresan N. Radiation therapy for spinal epidural metastases with complete block. Acta Radiol Oncol. 1983;22:135–43.CrossRef
11.
go back to reference Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
20.
go back to reference Lee I, Omodon M, Rock J, Shultz L, Ryu S. Stereotactic radiosurgery for high-grade metastatic epidural cord compression. J Radiosurg SBRT. 2014;3:51–8.PubMedPubMedCentral Lee I, Omodon M, Rock J, Shultz L, Ryu S. Stereotactic radiosurgery for high-grade metastatic epidural cord compression. J Radiosurg SBRT. 2014;3:51–8.PubMedPubMedCentral
23.
Metadata
Title
A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression
Authors
Dirk Rades
Antonio J. Conde-Moreno
Jon Cacicedo
Theo Veninga
Barbara Segedin
Karmen Stanic
Steven E. Schild
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-1203-y

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue